News
VBL craters as ovarian cancer gene therapy fails phase 3 tes...
Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported a phase 3 trial of its lead gene therapy VB-111 for ovarian cancer failed a p